Circulating Neutrophil Profiles Undergo a Dynamic Shift during Metabolic Dysfunction-Associated Steatohepatitis (MASH) Progression

被引:1
|
作者
Maretti-Mira, Ana C. [1 ]
Salomon, Matthew P. [1 ]
Chopra, Shefali [2 ]
Yuan, Liyun [1 ]
Golden-Mason, Lucy [1 ]
机构
[1] Univ Southern Calif, USC Res Ctr Liver Dis, Dept Med, Div Gastrointestinal & Liver Dis,Keck Sch Med, Los Angeles, CA 90033 USA
[2] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA
基金
美国国家卫生研究院;
关键词
metabolic dysfunction-associated steatotic liver disease (MASLD); innate immunity; transcriptomics; inflammation; metabolic dysfunction-associated steatohepatitis (MASH); neutrophils; FATTY LIVER-DISEASE; INNATE; CELLS; INFLAMMATION; MACROPHAGES; FIBROSIS; PROMOTES; BURDEN; SERVER; NAFLD;
D O I
10.3390/biomedicines12051105
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neutrophils play a crucial role in host defense against infection. Aberrant neutrophil activation may induce tissue damage via sterile inflammation. Neutrophil accumulation has been identified as a feature of the inflammatory response observed in metabolic dysfunction-associated steatohepatitis (MASH) and has been associated with liver fibrosis and cirrhosis. Here, we performed the transcriptomic analysis of circulating neutrophils from mild and advanced MASH patients to identify the potential mechanism behind neutrophil contribution to MASH progression. Our findings demonstrated that circulating neutrophils from mild and advanced MASH display an increased activated transcriptional program, with the expression of pro-inflammatory factors and an amplified lifespan compared to cells from non-diseased controls. Our results also suggest that MASH progression is associated with a dynamic shift in the profile of circulating neutrophils. In the early stages of MASH, mature neutrophils predominate in the bloodstream. As hepatic inflammation and fibrosis progress, the premature release of immature neutrophils into the circulation occurs. These immature neutrophils exhibit a pro-inflammatory profile that may exacerbate inflammation and promote fibrosis in MASH.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Identification of biomarkers for the diagnosis in colorectal polyps and metabolic dysfunction-associated steatohepatitis (MASH) by bioinformatics analysis and machine learning
    Geng, Ying
    Li, Yifang
    Liu, Ge
    Jiao, Jian
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [42] New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024
    Wong, Shu Wei
    Yang, Yong-yu
    Chen, Hui
    Xie, Li
    Shen, Xi-zhong
    Zhang, Ning-ping
    Wu, Jian
    ACTA PHARMACOLOGICA SINICA, 2025,
  • [43] Non-invasive assessment of liver inflammation in metabolic dysfunction-associated steatohepatitis (MASH) using MRI cytometry
    Jiang, Xiaoyu
    Izzy, Manhal
    Washington, Kay
    Gore, John
    Xu, Junzhong
    JOURNAL OF HEPATOLOGY, 2024, 80 : S595 - S595
  • [44] METABOLISM AND THERAPEUTIC EFFECTS OF N-ACYL AMINO ACIDS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND ATHEROSCLEROSIS
    Anand, Sumit Kumar
    Das, Sandeep
    Lee, Jennifer
    Richard, Koral
    McKinney, Peyton
    Rohilla, Sumati
    Pandey, Nilesh
    Kumar, Dhananjay
    Pearson-Gallion, Brenna
    Wang, Lu
    Finney, Alexandra
    Zhang, Jifeng
    Sun, Duxin
    Liu, Wanqing
    Chen, Eugene
    Orr, Wayne
    Dhanesha, Nirav
    Yurdagul, Arif
    Rom, Oren
    HEPATOLOGY, 2024, 80
  • [45] DEGREE OF METABOLIC DYSFUNCTION IS LINKED TO STEATOHEPATITIS (MASH), FIBROSIS, AND HIGHER CARDIOVASCULAR RISK IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Kim, David
    Abboud, Yazan
    Ismail, Mohamed
    Goyal, Ritik Mahaveer
    Pyrsopoulos, Nikolaos
    Kim, Hyunseok
    Hajifathalian, Kaveh
    Al-Khazraji, Ahmed
    HEPATOLOGY, 2024, 80 : S441 - S442
  • [46] Development and validation of CLDQ-MASH: a disease specific health related quality of life instrument for patients with metabolic dysfunction-associated steatohepatitis (MASH)
    Younossi, Zobair
    Stepanova, Maria
    Younossi, Issah
    Racila, Andrei
    JOURNAL OF HEPATOLOGY, 2024, 80 : S101 - S102
  • [47] IMPROVED DIAGNOSTIC ACCURACY OF VIBRATION-CONTROLLED TRANSIENT ELASTOGRAPHY BASED TESTS IN IDENTIFYING METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND AT-RISK MASH IN OBESE AND LEAN INDIVIDUALS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Quek, Joo Wei Ethan
    Tan, En Ying
    Lee, Shi Yan
    Huang, Daniel
    Lee, Jonathan
    Teng, Margaret
    Ng, Cheng Han
    Syn, Nicholas
    Wee, Aileen
    Soon, Shook Ting Gwyneth
    Jumat, Nur Halisah
    Dan, Yock Young
    Muthiah, Mark
    HEPATOLOGY, 2024, 80 : S620 - S621
  • [48] Associations Between Laboratory Results and Mortality in Patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Diabetes and Antihypertensive Drug Status
    Guillot, Jordan
    Williams, Christopher
    Slatter, Shadera
    Lo Re, Vin
    Rentsch, Christopher T.
    Ge, Jin
    Rudrapatna, Vivek
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 558 - 558
  • [49] Pharmacokinetics of the selective glucocorticoid receptor modulator miricorilant in healthy volunteers and patients with presumed metabolic dysfunction-associated steatohepatitis (MASH)
    Custodio, Joseph M.
    Donaldson, Kirsteen
    Kunta, Jeevan
    Juneja, Kavita
    Alkhouri, Naim
    Hunt, Hazel J.
    JOURNAL OF HEPATOLOGY, 2024, 80 : S613 - S614
  • [50] CURRENT MULTI-DIMENSIONAL VIEW OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) GLOBAL EPIDEMIOLOGICAL RATES
    Charlton, Michael
    Fishman, Jesse
    Kim, Yestle
    Saal, Gauri
    HEPATOLOGY, 2024, 80 : S839 - S840